Lilly, the AI at the service of research
La farmacéutica emplea la tecnología para mejorar el desarrollo de medicamentos, optimizar los procesos de producción y acelerar los ensayos clínicos. Leer
The pharmaceutical industry is leveraging artificial intelligence to optimize its business, from research and development to production efficiency and regulatory documentation. The AI market in the biopharmaceutical industry is expected to reach $8,540 million this year and $154,100 million by 2034, growing at a 43.5% annual rate.
US pharmaceutical company Lilly, a leader in diabetes and weight loss treatments, is using AI in various stages of drug development, including production, and has partnered with several companies, including Superluminal Medicine, Creyon Bio, Nvidia, Chai Discovery, Insilico Medicine, and Profluent, to accelerate AI applications.
Lilly's investment in AI has led to increased production and efficiency, with its treatments Mounjaro and Zepbound generating $65,179 million in revenue in 2025, a 45% increase from the previous year.
Written by urgent.news from Expansion ES's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.
